» Articles » PMID: 29601493

De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary

Overview
Date 2018 Mar 31
PMID 29601493
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The population with intellectual disabilities is one of the most vulnerable groups in society. Medication use is the main therapeutic intervention in this population and psychotropic medications can be prescribed for mental health conditions and for challenging behaviors. Clinical experience of prescribers and pharmacists working with people with intellectual disabilities suggests that reducing or stopping psychotropic medication is not always straightforward. What is required is rational, rather than rationed, prescribing of psychotropic medications. Concerns of clinicians working with people with intellectual disabilities and both formal and informal carers can result in maintenance of the 'status quo.' Setting-related, carer-related and staff-related factors play an important role in the real world of people with intellectual disabilities. Optimizing medication regimens in the adult population with intellectual disabilities is complicated but it is recognized that efforts to improve the current state of medication utilization are required for many individuals with intellectual disabilities. Pharmacists have a responsibility to include the person and/or their carer in their efforts to promote optimization of psychotropic medication use in environment in which the person lives.

Citing Articles

Recent Updates on Risk and Management Plans Associated with Polypharmacy in Older Population.

Alshanberi A Geriatrics (Basel). 2022; 7(5).

PMID: 36136806 PMC: 9498769. DOI: 10.3390/geriatrics7050097.


Deprescribing-A Few Steps Further.

Sadowski C Pharmacy (Basel). 2018; 6(4).

PMID: 30314314 PMC: 6306757. DOI: 10.3390/pharmacy6040112.

References
1.
. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015; 63(11):2227-46. DOI: 10.1111/jgs.13702. View

2.
Sheehan R, Hassiotis A . Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry. 2016; 4(3):238-256. DOI: 10.1016/S2215-0366(16)30191-2. View

3.
Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015; 351:h4326. PMC: 4556752. DOI: 10.1136/bmj.h4326. View

4.
Heslop P, Blair P, Fleming P, Hoghton M, Marriott A, Russ L . The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study. Lancet. 2013; 383(9920):889-95. DOI: 10.1016/S0140-6736(13)62026-7. View

5.
Paton C, Bhatti S, Purandare K, Roy A, Barnes T . Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice. BMJ Open. 2016; 6(12):e013116. PMC: 5168692. DOI: 10.1136/bmjopen-2016-013116. View